Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
Abroad (travel likely)RecruitingPHASE4
Conditions
Non-small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
MaastrichtUMC, Maastricht, Limburg, Netherlands
Contact: Study coordinator (Paul Kruithof, PharmD, MSc)
Study leads
Lizza Hendriks, MD, PhD
Principal Investigator
Maastricht University Medical Centre+